Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

2(28.6%)

N/A

2(28.6%)

7Total

Phase 1(3)

Phase 2(2)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04561219Phase 2Completed

Nitazoxanide Therapy for Patients With COVID-19 Pneumonia

Role: collaborator

NCT04552483Phase 2Completed

Effects of Early Use of Nitazoxanide in Patients With COVID-19

Role: collaborator

NCT02693366Phase 1Completed

Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis

Role: collaborator

NCT02653352Not ApplicableCompleted

Prevention of Excessive Weight Gain by Discouraging Students From Drinking Sodas

Role: collaborator

NCT01239862Phase 1Completed

Safety of Stem Cells Intrabronchial Instillation for Silicosis

Role: collaborator

NCT01872624Not ApplicableCompleted

Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema

Role: collaborator

NCT00473057Phase 1Completed

Study of Autologous Stem Cell Transplantation for Patients With Ischemic Stroke

Role: collaborator

All 7 trials loaded